Cybermedlife - Therapeutic Actions Hormone Replacement Therapy

Is migraine a consequence of a loss of neurohormonal and metabolic integrity? A new hypothesis.

Abstract Title: Is migraine a consequence of a loss of neurohormonal and metabolic integrity? A new hypothesis. Abstract Source: Neuro Endocrinol Lett. 2015 ;36(5):421-9. PMID: 26707041 Abstract Author(s): Sergey A Dzugan, Konstantine S Dzugan Article Affiliation: Sergey A Dzugan Abstract: OBJECTIVE: In 2002 we suggested a new hypothesis of migraine. This hypothesis implies that migraine is a consequence of a loss of neurohormonal and metabolic integrity. The goal of this clinical analysis is to present the evaluation of the effect of a multimodal treatment program in migraine management. MATERIAL AND METHODS: We evaluated 30 patients ages 16-66 with migraine who were treated with a multimodal treatment program. All patients received a complex program which included: hormonorestorative therapy (HT) with bio-identical hormones; correction of balance between sympathetic and parasympathetic systems and simultaneously calcium/magnesium balance;"resetting"the pineal gland; improvement of intestinal absorption through restoration of normal intestinal flora, and a cleanse from parasitic infestation (if necessary). Serum levels of total cholesterol (TC), pregnenolone, dehydroepiandrosterone sulfate (DHEAS), progesterone, total estrogen, and total testosterone were determined, RESULTS: All patients responded to this regimen. We do not have patients who still have migraine after they started to use this program. Laboratory finding prior to HT showed the significant deficiency in production of all basic steroid hormones (progesterone and pregnenolone production declined the most). Concurrent symptoms such as fibromyalgia, insomnia, depression, gastrointestinal disorders, and fatigue had disappeared. Total cholesterol completely normalized in 22 (91.7%) patients. No adverse effects or complications related to this program were registered. CONCLUSIONS: Our findings support the hypothesis that migraine is a consequence of a loss of neurohormonal and metabolic integrity, and that migraine can be managed by a multimodal approach. Article Published Date : Dec 31, 2014

Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients. 📎

Abstract Title: Hormone replacement therapy in morphine-induced hypogonadic male chronic pain patients. Abstract Source: Reprod Biol Endocrinol. 2011;9:26. Epub 2011 Feb 18. PMID: 21332999 Abstract Author(s): Anna Maria Aloisi, Ilaria Ceccarelli, Maria Carlucci, Annalisa Suman, Gianfranco Sindaco, Sergio Mameli, Valentina Paci, Laura Ravaioli, Giandomenico Passavanti, Valeria Bachiocco, Gilberto Pari Article Affiliation: Department of Physiology, Section of Neuroscience and Applied Physiology, University of Siena, Siena, Italy. This email address is being protected from spambots. You need JavaScript enabled to view it. Abstract: BACKGROUND: In male patients suffering from chronic pain, opioid administration induces severe hypogonadism, leading to impaired physical and psychological conditions such as fatigue, anaemia and depression. Hormone replacement therapy is rarely considered for these hypogonadic patients, notwithstanding the various pharmacological solutions available. METHODS: To treat hypogonadism and to evaluate the consequent endocrine, physical and psychological changes in male chronic pain patients treated with morphine (epidural route), we tested the administration of testosterone via a gel formulation for one year. Hormonal (total testosterone, estradiol, free testosterone, DHT, cortisol), pain (VAS and other pain questionnaires), andrological (Ageing Males' Symptoms Scale-AMS) and psychological (POMS, CES-D and SF-36) parameters were evaluated at baseline (T0) and after 3, 6 and 12 months (T3, T6, T12 respectively). RESULTS: The daily administration of testosterone increased total and free testosterone and DHT at T3, and the levels remained high until T12. Pain rating indexes (QUID) progressively improved from T3 to T12 while the other pain parameters (VAS, Area%) remained unchanged. The AMS sexual dimension and SF-36 Mental Index displayed a significant improvement over time. CONCLUSIONS: In conclusion, our results suggest that a constant, long-term supply of testosterone can induce a general improvement of the male chronic pain patient's quality of life, an important clinical aspect of pain management. Article Published Date : Jan 01, 2011
Therapeutic Actions Hormone Replacement Therapy

NCBI pubmed

Hormone therapy should not be prescribed for primary prevention of chronic medical conditions in asymptomatic postmenopausal women.

Related Articles Hormone therapy should not be prescribed for primary prevention of chronic medical conditions in asymptomatic postmenopausal women. BMJ Evid Based Med. 2018 12;23(6):231-232 Authors: Hilton C, Boardman H PMID: 30007912 [PubMed - indexed for MEDLINE]
Cookies make it easier for us to provide you with our services. With the usage of our services you permit us to use cookies.
More information Ok Decline